Novo Nordisk plans to invest $4.1 billion in a new manufacturing facility in Clayton, North Carolina, to boost production of their popular drugs Wegovy and Ozempic. The facility aims to meet rising global demand for effective obesity and diabetes treatments, while also fostering local economic growth and advancements in manufacturing technology.
Medicamen Organics announces its IPO price band at ₹32-34 per share. This article covers the key details, including GMP, financial performance, and future prospects of the SME IPO in the pharmaceutical sector.
